secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001558370-23-014396
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios Q2 net loss $1.4M ($0.08/share); cash $4.6M; FDA IMC-1 toxicology adequate; pK study planned
--------------------------------------------------------------------------------

- Net loss $1.4M ($0.08 per share) vs $3.7M ($0.44) in Q2 2022; R&D down to $0.6M, G&A down to $0.9M.
- Cash $4.6M at June 30, plus $1.4M raised via July Sales Agreement; runway at least 12 months.
- FDA indicates IMC-1 chronic toxicology program adequate to support Phase 3 fibromyalgia study.
- Pk/food-effect study planned for H2 2023; first Phase 3 FM study enrollment targeted for mid-2024.
- IMC-2 Long-COVID: new double-blind placebo-controlled study with Bateman Horne Center; FDA meeting to discuss Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/0001558370-23-014396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/tmb-20230810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer